Vesole Adam S, Breen Joseph T
Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH.
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Jacksonville, Jacksonville, FL.
Otol Neurotol. 2025 Aug 1;46(7):753-758. doi: 10.1097/MAO.0000000000004415. Epub 2025 Jan 22.
To identify the incidence of positive autoimmune laboratory markers in idiopathic sudden sensorineural hearing loss (iSSNHL) and its impact on hearing prognosis.
Retrospective cohort database study.
A collaborative national database (TriNetX) sourced from 79 large healthcare organizations in the United States.
Adults (≥18 years old) diagnosed with iSSNHL (ICD-10 H91.2) treated with systemic steroids.
Autoimmune laboratory markers and salvage intratympanic (IT) steroids for SSNHL (CPT 69801).
Subjects with iSSNHL who had autoimmune testing (n = 17,413) were marginally more likely to be positive for at least one autoimmune laboratory marker compared to subjects without iSSNHL (n = 17,413; 23.0% vs. 21.4%, p = 0.0006). Statistical significance was lost after removing nonspecific autoimmune markers, however. Of those with iSSNHL who received systemic steroid treatment, subjects with positive autoimmune markers (n = 5,153) versus negative autoimmune markers (n = 5,153) underwent similar rates of salvage IT steroids (7.1% vs. 7.8%, p = 0.154), hearing aid evaluation (2.76% vs 2.47%, p = 0.354), and cochlear implantation (1.65% vs. 1.69%, p = 0.878).
Patients with iSSNHL have a marginally higher incidence of nonspecific positive autoimmune laboratory markers compared to those without iSSNHL; however, the presence of these markers does not predict treatment response or prognosis. Specifically, autoimmune markers did not predict the need for salvage IT steroids, nor CI and hearing aid use in iSSNHL. Autoimmune laboratory testing may be useful in iSSNHL patients with additional symptoms suspicious for an autoimmune disorder; however, a generalized screening is not recommended as it is unlikely to alter management or prognosis.
确定特发性突发性感音神经性听力损失(iSSNHL)中自身免疫实验室指标阳性的发生率及其对听力预后的影响。
回顾性队列数据库研究。
一个来自美国79家大型医疗保健机构的合作性全国数据库(TriNetX)。
诊断为iSSNHL(国际疾病分类第十版H91.2)并接受全身类固醇治疗的成年人(≥18岁)。
自身免疫实验室指标以及用于SSNHL的挽救性鼓室内(IT)类固醇(现行程序编码69801)。
1)自身免疫实验室指标的阳性情况——类风湿因子(RF)、抗中性粒细胞胞浆抗体(ANCA)、双链DNA抗体(Ab)、干燥综合征A和B抗体、SCL - 70抗体、心磷脂IgG抗体、Jo - 1抗体、抗核抗体(ANA)、线粒体抗体。2)接受挽救性IT类固醇治疗、人工耳蜗植入或助听器评估的患者百分比——所有这些都用作听力结果的替代指标。
与未患iSSNHL的受试者(n = 17413)相比,进行了自身免疫检测的iSSNHL受试者(n = 17413)至少有一种自身免疫实验室指标呈阳性的可能性略高(23.0%对21.4%,p = 0.0006)。然而,去除非特异性自身免疫指标后,统计学显著性消失。在接受全身类固醇治疗的iSSNHL患者中,自身免疫指标阳性的受试者(n = 5153)与自身免疫指标阴性的受试者(n = 5153)接受挽救性IT类固醇治疗的比例相似(7.1%对7.8%,p = 0.154),助听器评估比例相似(2.76%对2.47%,p = 0.354),人工耳蜗植入比例也相似(1.65%对1.69%,p = 0.878)。
与未患iSSNHL的患者相比,iSSNHL患者非特异性自身免疫实验室指标阳性的发生率略高;然而,这些指标的存在并不能预测治疗反应或预后。具体而言,自身免疫指标不能预测iSSNHL患者是否需要挽救性IT类固醇治疗,也不能预测人工耳蜗植入和助听器的使用情况。自身免疫实验室检测可能对有其他自身免疫性疾病可疑症状的iSSNHL患者有用;然而,不建议进行普遍筛查,因为这不太可能改变治疗管理或预后。